EP Patent

EP3011030B1 — Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation

Assigned to Massachusetts Institute of Technology · Expires 2023-11-08 · 3y expired

What this patent protects

Patent listed against Onpattro.

Drugs covered by this patent

Patent Metadata

Patent number
EP3011030B1
Jurisdiction
EP
Classification
—
Expires
2023-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Massachusetts Institute of Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.